Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.50 |
| ▸ | DRD3 | P35462 | 9/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686705 | 1.00 | DRD2 (0.50) | DRD2DRD3DRD4IDO1MET | |
| SCHEMBL4684880 | 0.91 | DRD2 (0.39) | DRD2DRD3DRD4IDO1MET | |
| SCHEMBL4689438 | 0.91 | DRD2 (0.39) | DRD2DRD3DRD4IDO1MET | |
| SCHEMBL4687312 | 0.91 | DRD2 (0.39) | DRD2DRD3DRD4IDO1MET | |
| SCHEMBL4688203 | 0.79 | DRD3 (0.49) | DRD2DRD3IDO1MET | |
| SCHEMBL4687244 | 0.79 | DRD3 (0.49) | DRD2DRD3IDO1MET | |
| SCHEMBL4686484 | 0.74 | SLC6A4 (0.44) | DRD2IDO1METNOS1AXL | |
| SCHEMBL5231526 | 0.72 | DRD2 (0.60) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL4688304 | 0.70 | DRD2 (0.44) | DRD2DRD3DRD4KCNH2OPRM1 | |
| SCHEMBL4683948 | 0.70 | DRD2 (0.44) | DRD2DRD3DRD4KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753763-B1 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LTD (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1753763-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | Pfizer Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116027-A2 | INDAZOLE AND INDOLONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | PFIZER LIMTED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | PFIZER INC | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267096-A1 | New indazole and indolone derivatives and their use pharmaceuticals | DRD2, DRD3, DRD1 | DRD2 1/4885DRD3 2/4885DRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.